Katherine P. Cabral, Pharm.D., BCPS



Cardiology Specialty Residency, Boston Medical Center, Boston MA
Pharmacy Practice Residency, Boston Medical Center, Boston MA
Pharm.D., Northeastern University, Bouve College of Health Sciences, Boston MA

Courses Taught at ACPHS

Integrated Problem Solving (IPS) Workshop 4
Advanced Pharmacy Practice Experience - Cardiology
PTPM Cardiovascular module

Research Interests

Novel anticoagulants
Prevention and treatment of venous thromboembolism disease
Heparin induced thrombocytopenia
Acute coronary syndromes pharmacotherapy
Antithrombotic reversal

Selected Publications

Boden WE, Padala SK, Cabral KP, Buschmann I, Sidhu MS. The Role of Short-Acting Nitroglycerin in the Management of Ischemic Heart Disease. Drug Design, Development and Therapy 2015; 9:4793-4805.

Cabral KP, Ansell JE. The Role of Factor Xa Inhibitors in VTE Treatment. Vasc Health Risk Manag Jan 2015; 11:117-123.

Croft PE, Cabral KP, Strout TD, Baumann MR, Gibbs MA, DeLaney MC.  Managing Blunt Trauma in Patients on Dabigatran Etexilate: Case Study and Review of the Literature. J Emerg Nursing 2013; 39(3):302-308.

Cabral KP, Fraser GL, Duprey J, Gibbons BA, Hayes T, Florman JE, Seder DB. Prothrombin Complex Concentrates to Reverse Warfarin-Induced Coagulopathy in Patients with Intracranial Bleeding. Clin Neuro Neurosurg 2013 Jun; 115(6):770-4.

 Mantha S, Cabral KP, Ansell JA. New Avenues for Anticoagulation in Atrial Fibrillation. Clin Pharm Ther 2013; 93(1):68-77.

Cabral KP, Ansell JA. Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation. Nat Rev Cardiol 2012; advance online publication 2.28.12; doi:10.1038/nrcardio.2012.19.

Runyan CL, Cabral KP, Riker RR, et al. “Bivalirudin Doses Correlate with Creatinine Clearance During Treatment of Heparin- Induced Thrombocytopenia: A Retrospective Chart Review.” Pharmacotherapy 2011: Pharmacotherapy 2011;31(9):850-856. 

Cabral KP, Ansell JA. Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation. Nat Rev Cardiol 2012; 9:385-391. doi:10.1038/nrcardio.2012.19

Rolfe S, Papadopoulos S, Cabral KP. “Controversies of Anticoagulation Reversal in Life Threatening Bleeds.” J Pharm Pract 2010; 23: 217-225. 

Phillips KW, Ansell JA. “The Clinical Implications of New Oral Anticoagulants: Will the Potential Advantages be Achieved?” Thromb Haemost 2010;103:34-39. Cabral, KP. "How to meet national quality initiatives: best practices.” J Thromb Thrombolysis2009; 29(2): 105. 

Phillips KW, Dobesh PP, Haines ST. “Considerations in Using Anticoagulant Therapy in Special Patient Populations” AJHP 2008; 65 (suppl 7):S13-21. 

Phillips KW, Merli G.  “Chapter 10: Developing an Inpatient Anticoagulation Service”Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. 3rdedition. Wolters Kluwer Health, Inc.: 2009.

Assistant Professor
Department of Pharmacy Practice